Αρχική World News Exosomes May Help Tumors Evade Immune System

Exosomes May Help Tumors Evade Immune System

September 7, 2018, by NCI Staff

A transmission electron micrograph of a cancerous B cell that has secreted exosomes.

Credit: BMC Biology 2016. https://doi.org/10.1186/s12915-016-0268-z. CC BY 4.0.

A new study has identified what may be an important and previously unknown route by which tumors evade the immune system: They secrete small membrane-encased sacs, called exosomes, that are studded with a protein that dials down the immune response.

The study, led by researchers at the University of Pennsylvania, found that in lab models of the skin cancer melanoma and in humans with the disease, tumor cells release exosomes coated with proteins called PD-L1. These proteins are part of a family of immune checkpoint proteins that bind to partner molecules on immune cells, effectively deactivating them.

The researchers likened the PD-L1-studded exosomes to a fleet of drones engaged in preemptive strikes, moving throughout the body to thwart an antitumor attack before immune cells—namely those known as cytotoxic T cells—ever have a chance to reach the tumor.

Findings from the study, published August 8 in Nature, also raise the possibility that measuring levels of PD-L1 on exosomes in patient blood samples could help to guide treatment decisions, said study co-leader Xiaowei Xu, M.D., Ph.D.

Although the study’s findings are provocative, it’s still too early to know to what extent exosomes carrying PD-L1 influence the immune response against tumors in people with melanoma, said Suzanne Topalian, M.D., associate director of the Bloomberg-Kimmel Institute for Cancer Immunotherapy at Johns Hopkins University.

“There are still many, many questions” to address before reaching that conclusion, said Dr. Topalian, who was not involved in the study. And the study also raises other questions, she added.

Among them, she said: “What other types of immune-modulating molecules might be on the surface of these exosomes?”

Following the Evidence Trail

For many years, scientists thought exosomes served strictly as molecular garbage trucks, transporting waste out of cells. But it’s become clear that extracellular vesicles like exosomes influence a variety of biological processes, said Jennifer Jones, M.D., Ph.D., of NCI’s Center for Cancer Research.

Researchers have known for some time that “exosomes have important roles in cancer and in the immune system,” Dr. Jones said. “But it has been difficult to know which exosomes do what.”

The volume of each exosome is one million times smaller than the volume of a typical cell, she continued, and “most of the tools of modern biomedical research are not suitable for precise and functional analyses of the cargo within individual exosomes.”

Based on some earlier studies that found PD-L1 in blood samples and different types of vesicles released by cancer and other cells, the Penn team used a broad approach to look more closely at PD-L1 in these cellular outcasts to see if they influence the immune system’s interaction with tumors.

On the Surface of Tumor Cells and Exosomes

Melanoma is known for eliciting a particularly strong immune response, and several immune checkpoint inhibitors have been approved by the Food and Drug Administration to treat melanoma. So the researchers began by evaluating different melanoma cell lines.

Right away they were surprised by what they found, Dr. Xu said.

Exosomes released from melanoma cells did contain PD-L1, they confirmed. Moreover, the exosomes from metastatic melanoma cells contained far more PD-L1 than cells from an initial, or primary, melanoma tumor.

The surprise came when they used electron microscopy to get a detailed view of the exosomes. The PD-L1 proteins were not inside the exosomes. Rather, the proteins were carried on their surface, with the binding portion of the protein protruding outside the surface—just as it does on tumor cells.

“That got us really excited, because if that’s the case, that means the exosomal PD-L1 can directly interact with T cells,” said Dr. Xu.

Further experiments confirmed that possibility. The team showed that the exosomes could bind to cytotoxic T cells—the immune cells most involved in directly killing cancer cells—and prevent them from proliferating and killing cancer cells.

When they moved their work to mouse models of melanoma, the research team also found exosomes studded with PD-L1 on their surface. Using a mouse model of melanoma that more closely mimics human cancer, injecting the mice with exosomes with PD-L1 on their surface made the tumors grow faster and reduced the accumulation of T cells and other immune cells in and around tumors.

A Treatment Biomarker?

The research team next looked at blood samples collected from people who had been treated for melanoma, and again they saw exosomes coated with PD-L1. They also found extracellular vesicles, most commonly exosomes, carrying PD-L1 in blood samples collected from people who had been treated for breast and lung cancers.

Their work raised an interesting possibility: that levels of PD-L1 on exosomes could be used to potentially identify patients who are most likely to respond to checkpoint inhibitors or to track their response to these drugs, Dr. Xu said.

For example, they analyzed blood samples from people who had been treated for melanoma with the checkpoint inhibitor pembrolizumab (Keytruda), which blocks PD-1, the immune cell binding partner of PD-L1. Patients whose tumors responded best to the drug had much lower exosomal PD-L1 levels before treatment than those who did not respond. And patients with the highest pretreatment levels of exosomal PD-L1 had worse outcomes than those with lower levels.

Exosomal PD-L1 levels measured after treatment began, however, told a different story. Patients who had large increases anywhere from 3–6 weeks after beginning treatment were much more likely to have reductions in the size of their tumors than those who had smaller increases.

Although the findings appear to be contradictory, they make biological sense, Dr. Xu said.

“It means there are two different processes going on,” he explained.

Before treatment, the exosomal PD-L1 levels likely reflect the size of the tumor or extent of the disease. Meaning, if the circulating PD-L1 is high, there’s a lot of tumor, which is associated with a poor prognosis.

After treatment with pembrolizumab, he said, “the rapid increase of exosomal PD-L1 [in treatment responders] means that the T cells are being activated, so they secrete more cytokines like IFN-gamma,” he said. Cytokines are signaling molecules that can stimulate the immune system.

In melanoma cell lines, in fact, the researchers showed that treating the cells with IFN-gamma increased exosomal PD-L1. And in their analysis of patient samples, they found that exosomal PD-L1 levels tended to rise and fall with IFN-gamma levels.

More Work to Do

The Penn team has “identified one important exosome population among a tremendously diverse repertoire of exosome populations that influence biological processes,” Dr. Jones said. “New tools and new approaches are needed to study these very small packages in more precise detail.”

Dr. Topalian stressed that further studies are needed, including those that involve a much larger number of samples from patients with melanoma—and more cancer types—and those that closely compare PD-L1 in tumor biopsies and tumor-released exosomes.

For example, work by Dr. Topalian’s lab and others has shown that only about 40% of human melanomas contain tumor cells expressing substantial levels of PD-L1 on their surface. Future studies, she said, should look to see if there is a correlation between the amount of PD-L1 in tumors and on exosomes from the same patient.

Also, the idea that there is a large amount of exosomal PD-L1 in the circulation of people with melanoma would imply that it’s having “a global effect on suppressing immunity” in those patients, she said. “And there’s no evidence that most patients with stage IV melanoma are globally immune suppressed.”

Source

NEWSLETTER

Συμπληρώστε το email σας για να λαμβάνετε τις σημαντικότερες ειδήσεις από το ogkologos.com

Βρείτε μας

2,449ΥποστηρικτέςΚάντε Like
57ΑκόλουθοιΑκολουθήστε

Διαβαστε Επίσης

ΕΞΕΛΙΞΕΙΣ ΣΤΗ ΘΕΡΑΠΕΙΑ ΤΟΥ ΜΗ-ΜΙΚΡΟΚΥΤΤΑΡΙΚΟΥ ΚΑΡΚΙΝΟΥ ΤΟΥ ΠΝΕΥΜΟΝΑ (ΜΜΚΠ)

ΕΞΕΛΙΞΕΙΣ ΣΤΗ ΘΕΡΑΠΕΙΑ ΤΟΥ ΜΗ-ΜΙΚΡΟΚΥΤΤΑΡΙΚΟΥ ΚΑΡΚΙΝΟΥ ΤΟΥ ΠΝΕΥΜΟΝΑ (ΜΜΚΠ) Γράφει ο Δρ Παπαδούρης Σάββας, Παθόλογος-Ογκολόγος   Ο ΜΜΚΠ βρίσκεται αναλογικά στο 80% και πλέον του συνολικού...

Διατρέχουν όντως οι καρκινοπαθείς μεγαλύτερο κίνδυνο λόγω κοροναϊού;

Σε πρακτικό επίπεδο, τα δεδομένα των σχετικών μελετών υποδηλώνουν ότι η χημειοθεραπεία ή οι άλλες αντι-νεοπλασματικές θεραπείες δεν αυξάνουν σημαντικά τον κίνδυνο θνησιμότητας από...

FDA: Η ακτινοβολία των smartphones δεν προκαλεί καρκίνο

Σε μια νέα έκθεσή της, η Υπηρεσία Τροφίμων και Φαρμάκων (FDA) των ΗΠΑ αναφέρει ότι επανεξέτασε τις σχετικές επιστημονικές έρευνες που δημοσιεύθηκαν τα τελευταία...

Νέα ανακάλυψη, νέα ελπίδα για τον καρκίνο

Ένα νεοανακαλυφθέν τμήμα του ανοσοποιητικού μας συστήματος θα μπορούσε να αξιοποιηθεί για την αντιμετώπιση όλων των ειδών καρκίνου, σύμφωνα με επιστήμονες του πανεπιστημίου Cardiff...

Καρκίνος: Ευεργετική για τους καρκινοπαθείς η άσκηση

Σημαντικά ωφέλη προσφέρει η άσκηση, ακόμη και σε ασθενείς με καρκίνο. Οι περισσότεροι ασθενείς αγνοούν τα οφέλη που μπορεί να έχει γι’ αυτούς η συχνή...

Prostate Cancer

The article is provided by Scientific Communications Officer of NIPD Genetics, Ms Marina Charitou (MSc) Prostate Cancer Awareness Prostate cancer is the second most common cancer...
- Advertisment -

Ροή Ειδήσεων

Targeted Therapy Based on Molecular Profiling of Malignant Mesothelioma Tumours Is Feasible

Targeted therapy recommendations can be made based on the molecular profiles of tumour samples from patients with metastatic malignant mesothelioma (MM) according to findings...

News digest – targeted radiation beam, precision medicine and our early detection roadmap

<img width="620" height="348" src="https://zniup3zx6m0ydqfpv9y6sgtf-wpengine.netdna-ssl.com/wp-content/uploads/2020/10/Radiation_hero-1.jpg" class="attachment-hero size-hero" alt srcset="https://zniup3zx6m0ydqfpv9y6sgtf-wpengine.netdna-ssl.com/wp-content/uploads/2020/10/Radiation_hero-1.jpg 620w, https://zniup3zx6m0ydqfpv9y6sgtf-wpengine.netdna-ssl.com/wp-content/uploads/2020/10/Radiation_hero-1-300x168.jpg 300w, https://zniup3zx6m0ydqfpv9y6sgtf-wpengine.netdna-ssl.com/wp-content/uploads/2020/10/Radiation_hero-1-220x123.jpg 220w, https://zniup3zx6m0ydqfpv9y6sgtf-wpengine.netdna-ssl.com/wp-content/uploads/2020/10/Radiation_hero-1-150x84.jpg 150w" sizes="(max-width: 620px) 100vw, 620px" data-attachment-id="18059" data-permalink="https://scienceblog.cancerresearchuk.org/2020/10/17/news-digest-targeted-radiation-beam-precision-medicine-and-our-early-detection-roadmap/radiation_hero-3/" data-orig-file="https://scienceblog.cancerresearchuk.org/wp-content/uploads/2020/10/Radiation_hero-1.jpg" data-orig-size="620,348" data-comments-opened="1"...

A Pet Pug Helped Two Sisters Realize They Both Had Breast Cancer

Sisters Amanda Tasca and Amy Niosi are grateful for one very perceptive pug. Amanda’s dog Daisy, a gift from her husband Steve and one...

Woman with Breast Cancer May Have Saved Her Twin’s Life by Revealing Her Lumpectomy Scar

When Meagan McCallum was diagnosed with breast cancer, she had no idea that her experience might actually save her sister’s life. Meagan underwent a...

Lo que debe saber sobre el cáncer de pulmón

La Dra. Jyoti D. Patel es profesora de Medicina y directora de Oncología Torácica de la Universidad de Chicago y es editora asociada para...

Alternatives for Outdoor Foods

Autumn has arrived, but that doesn’t mean outdoor dining has to end! You might be wondering what foods you could prepare that are healthy...